Functional validation established GABARAP as a central oncogenic regulator orchestrating synergistic mitophagy flux and pyruvate metabolic reprogramming, thereby identifying GABARAP as a promising therapeutic target for osteosarcoma progression. Here, GABARAP is linked to osteosarcoma.